MDT

95.15

-0.07%↓

VEEV

282.94

-3.66%↓

A

141.87

-0.84%↓

HQY

91.42

+0.47%↑

TLRY

1.54

-1.91%↓

MDT

95.15

-0.07%↓

VEEV

282.94

-3.66%↓

A

141.87

-0.84%↓

HQY

91.42

+0.47%↑

TLRY

1.54

-1.91%↓

MDT

95.15

-0.07%↓

VEEV

282.94

-3.66%↓

A

141.87

-0.84%↓

HQY

91.42

+0.47%↑

TLRY

1.54

-1.91%↓

MDT

95.15

-0.07%↓

VEEV

282.94

-3.66%↓

A

141.87

-0.84%↓

HQY

91.42

+0.47%↑

TLRY

1.54

-1.91%↓

MDT

95.15

-0.07%↓

VEEV

282.94

-3.66%↓

A

141.87

-0.84%↓

HQY

91.42

+0.47%↑

TLRY

1.54

-1.91%↓

Search

Anavex Life Sciences Corp

Abierto

SectorSanidad

9.08 -0.77

Resumen

Variación precio

24h

Actual

Mínimo

8.72

Máximo

9.21

Métricas clave

By Trading Economics

Ingresos

-2M

-13M

Empleados

42

EBITDA

-2.1M

-13M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+365.12% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-229M

740M

Apertura anterior

9.85

Cierre anterior

9.08

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

170 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Anavex Life Sciences Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

16 oct 2025, 21:10 UTC

Principales Movimientos del Mercado

Kezar Life Sciences Shares Surge After Break with FDA, Restructuring Plan

16 oct 2025, 19:03 UTC

Adquisiciones, fusiones, absorciones

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- 2nd Update

16 oct 2025, 17:58 UTC

Adquisiciones, fusiones, absorciones

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- Update

16 oct 2025, 17:12 UTC

Ganancias

Ray-Ban Maker EssilorLuxottica's Revenue Surges to Quarterly Record -- Update

16 oct 2025, 17:12 UTC

Adquisiciones, fusiones, absorciones

Canada Signals Limited Concern Over US Government Stakes in Canadian Miners

16 oct 2025, 16:59 UTC

Adquisiciones, fusiones, absorciones

Airbus's Takeover of Spirit AeroSystems Plants Gets French Antitrust Clearance

16 oct 2025, 23:44 UTC

Charlas de Mercado

Gold Climbs Amid Safe-Haven Demand -- Market Talk

16 oct 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Fall, Tracking Wall Street's Declines -- Market Talk

16 oct 2025, 23:42 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 oct 2025, 22:15 UTC

Ganancias

China Tower: Results Supported by Higher Contributions From Energy, Smart Tower Business >0788.HK

16 oct 2025, 22:15 UTC

Ganancias

China Tower 9-Mos Rev CNY74.32B Vs. CNY72.45B >0788.HK

16 oct 2025, 22:15 UTC

Ganancias

China Tower 9-Mos Net CNY8.71B Vs. Net CNY8.15B >0788.HK

16 oct 2025, 22:02 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 oct 2025, 22:02 UTC

Charlas de Mercado

Santos Drifts Into 'Oversold Territory' -- Market Talk

16 oct 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

16 oct 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Health Care Roundup: Market Talk

16 oct 2025, 20:23 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 oct 2025, 20:23 UTC

Charlas de Mercado

Recession Risks to Push Canada Toward October Rate Cut -- Market Talk

16 oct 2025, 20:20 UTC

Ganancias

These Stocks Moved the Most Today: TSMC, Salesforce, HPE, F5, United Airlines, Travelers, J.B. Hunt, Praxis Precision, and More -- Barrons.com

16 oct 2025, 20:08 UTC

Adquisiciones, fusiones, absorciones

Jack in the Box to Sell Del Taco With Big Markdown. The Stock Plunged. -- Barrons.com

16 oct 2025, 19:37 UTC

Adquisiciones, fusiones, absorciones

Crypto Industry Dives Deeper Into Prediction Markets as Kraken Buys Exchange -- Barrons.com

16 oct 2025, 19:26 UTC

Ganancias

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 oct 2025, 19:24 UTC

Charlas de Mercado

U.S. Natural Gas Falls on Mild Weather, Ample Storage -- Market Talk

16 oct 2025, 19:23 UTC

Charlas de Mercado

Oil Falls As Oversupply Concerns Outweigh India News -- Market Talk

16 oct 2025, 19:23 UTC

Ganancias

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 oct 2025, 18:35 UTC

Charlas de Mercado
Ganancias

Charles Schwab Logs Another Quarter of Record Revenues, Earnings -- Market Talk

16 oct 2025, 18:31 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 oct 2025, 18:31 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 oct 2025, 18:31 UTC

Charlas de Mercado

Charles Schwab Readies Spot Crypto Trading -- Market Talk

16 oct 2025, 16:57 UTC

Charlas de Mercado

Oil Futures Lose Ground as EIA Reports Crude Stock Build -- Market Talk

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp previsión

Precio Objetivo

By TipRanks

365.12% repunte

Estimación a 12 Meses

Media 42 USD  365.12%

Máximo 42 USD

Mínimo 42 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.275 / 9.312Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

170 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
help-icon Live chat